Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2006 2
2007 3
2008 2
2010 3
2012 3
2013 4
2014 2
2015 2
2016 4
2017 9
2018 6
2019 13
2020 23
2021 29
2022 17
2023 21
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study.
Oliva M, Heirali A, Watson G, Rooney AM, Cochrane K, Jennings S, Taylor R, Xu M, Hosni A, Hope A, Bratman SV, Chepeha D, Weinreb I, Perez-Ordonez B, Nin RM, Waldron J, Xu W, Hansen AR, Siu LL, Coburn B, Spreafico A. Oliva M, et al. Among authors: spreafico a. Br J Cancer. 2024 May 7. doi: 10.1038/s41416-024-02701-y. Online ahead of print. Br J Cancer. 2024. PMID: 38714747
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.
Spreafico A, Couselo EM, Irmisch A, Bessa J, Au-Yeung G, Bechter O, Svane IM, Sanmamed MF, Gambardella V, McKean M, Callahan M, Dummer R, Klein C, Umaña P, Justies N, Heil F, Fahrni L, Opolka-Hoffmann E, Waldhauer I, Bleul C, Staack RF, Karanikas V, Fowler S. Spreafico A, et al. Front Oncol. 2024 Mar 21;14:1346502. doi: 10.3389/fonc.2024.1346502. eCollection 2024. Front Oncol. 2024. PMID: 38577337 Free PMC article.
Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.
Sanz-Garcia E, Zou J, Avery L, Spreafico A, Waldron J, Goldstein D, Hansen A, Cho BCJ, de Almeida J, Hope A, Hosni A, Hahn E, Perez-Ordonez B, Zhao Z, Smith C, Zheng Y, Singaravelan N, Bratman SV, Siu LL. Sanz-Garcia E, et al. Among authors: spreafico a. Cell Death Differ. 2024 Apr;31(4):460-468. doi: 10.1038/s41418-024-01272-y. Epub 2024 Feb 26. Cell Death Differ. 2024. PMID: 38409276 Free PMC article.
Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors.
Stutheit-Zhao EY, Sanz-Garcia E, Liu ZA, Wong D, Marsh K, Abdul Razak AR, Spreafico A, Bedard PL, Hansen AR, Lheureux S, Torti D, Lam B, Yang SYC, Burgener J, Luo P, Zeng Y, Cheng N, Awadalla P, Bratman SV, Ohashi PS, Pugh TJ, Siu LL. Stutheit-Zhao EY, et al. Among authors: spreafico a. Cancer Discov. 2024 Feb 23. doi: 10.1158/2159-8290.CD-23-1060. Online ahead of print. Cancer Discov. 2024. PMID: 38393391
Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data.
Hernando-Calvo A, Nguyen P, Bedard PL, Chan KKW, Saleh RR, Weymann D, Yu C, Amir E, Regier DA, Gyawali B, Kain D, Wilson B, Earle CC, Mittmann N, Abdul Razak AR, Isaranuwatchai W, Sabatini P, Spreafico A, Stockley TL, Pugh TJ, Williams C, Siu LL, Hanna TP. Hernando-Calvo A, et al. Among authors: spreafico a. EClinicalMedicine. 2024 Feb 12;69:102443. doi: 10.1016/j.eclinm.2024.102443. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38380071 Free PMC article.
Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient.
Lien SC, Ly D, Yang SYC, Wang BX, Clouthier DL, St Paul M, Gadalla R, Noamani B, Garcia-Batres CR, Boross-Harmer S, Bedard PL, Pugh TJ, Spreafico A, Hirano N, Razak ARA, Ohashi PS. Lien SC, et al. Among authors: spreafico a. Nat Commun. 2024 Feb 6;15(1):1094. doi: 10.1038/s41467-024-45449-y. Nat Commun. 2024. PMID: 38321065 Free PMC article.
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers.
Kazandjian S, Rousselle E, Dankner M, Cescon DW, Spreafico A, Ma K, Kavan P, Batist G, Rose AAN. Kazandjian S, et al. Among authors: spreafico a. Cancers (Basel). 2024 Jan 19;16(2):445. doi: 10.3390/cancers16020445. Cancers (Basel). 2024. PMID: 38275886 Free PMC article.
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der Wekken AJ, Ascierto PA, Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F, Buigues A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer R. Janku F, et al. Among authors: spreafico a. Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458. Epub 2023 Nov 21. Eur J Cancer. 2024. PMID: 38039779 Clinical Trial.
137 results